Ocular Oncology News

BAP1 immunohistochemical staining of primary uveal melanoma showed high capability to evaluate metastatic risk in a study.

BOSTON — Class 2 uveal melanoma tumors are associated with older age, tumor size, ciliary body involvement and exudative retinal detachment, according to a poster presented at the American Society of Retina Specialists meeting.

BOSTON — Uveal melanoma management is undergoing significant changes that enable improved survival for patients, improved globe retention and excellent visual acuity preservation, a speaker said here.

BOSTON — It takes teamwork to manage uveal melanoma, Carol L. Shields, MD, told colleagues at the American Society of Retina Specialists meeting,

The annual Women in Ophthalmology Summer Symposium will take place in San Diego from Aug. 10 to 13 with a restructured format, new content and more networking opportunities, meeting chair Lisa Nijm, MD, JD, told Healio.com/OSN.

Three important access milestones for DecisionDx-UM have been reached, Castle Biosciences announced in a press release.

Ophthalmic artery chemosurgery with intravitreous chemotherapy to treat class 3 retinoblastoma vitreous seeds resulted in a shorter time to regression compared with ophthalmic artery chemosurgery alone, according to a retrospective study.

Iris melanoma treated with palladium-103 plaque brachytherapy showed patterns of regression that included decreased intrinsic tumor vascularity, increased tumor pigmentation and decreased tumor thickness, according to a study.

AU-011, an investigational, first-in-class targeted therapy for ocular melanoma treatment, was granted fast track designation by the FDA, according to a press release from Aura Biosciences.

NEW YORK — Some clinical trials evaluating standard melanoma immunotherapies have been disappointing for metastatic uveal melanoma, Alexander Shoushtari, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, said at HemOnc Today Melanoma and Cutaneous Malignancies.